← Back to Search

Probiotic for Anxiety in Parkinson's Disease (TAP Trial)

Phase 2
Waitlist Available
Led By Silke Appel-Cresswell, MD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 13 weeks

Summary

This trial will study whether an oral probiotic can help relieve anxiety in people with Parkinson's Disease.

Eligible Conditions
  • Overactive Bladder
  • Anxiety
  • Parkinson's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~13 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 13 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Parkinson's Anxiety Scale (PAS)
Secondary study objectives
Beck Depression Inventory (BDI)
Fatigue Severity Scale (FSS)
Montreal Cognitive Assessment
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ProbioticExperimental Treatment1 Intervention
Ecologic® BARRIER 849 (Maize starch, maltodextrin, vegetable protein, potassium chloride, +/- probiotic bacteria (B. bifidum W23, B. lactis W51, B. lactis W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, Lc. lactis W19, Lc. lactis W58; ≥ 2,5\*10\^9 colony forming unit (CFU)/g), magnesium sulphate, manganese sulphate.) sachet, two times daily dosing for a total of 2 grams (viable cell count of 2.5 × 10\^9 CFU/gram) per day.
Group II: PlaceboPlacebo Group1 Intervention
Placebo (maize starch, maltodextrin, vegetable protein, magnesium sulphate, manganese sulphate)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Probiotic
2013
Completed Phase 4
~3570

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,466 Previous Clinical Trials
2,485,395 Total Patients Enrolled
The W. Garfield Weston FoundationUNKNOWN
3 Previous Clinical Trials
150 Total Patients Enrolled
Silke Appel-Cresswell, MDPrincipal InvestigatorUniversity of British Columbia
1 Previous Clinical Trials
50 Total Patients Enrolled

Media Library

Placebo Clinical Trial Eligibility Overview. Trial Name: NCT03968133 — Phase 2
Overactive Bladder Research Study Groups: Probiotic, Placebo
Overactive Bladder Clinical Trial 2023: Placebo Highlights & Side Effects. Trial Name: NCT03968133 — Phase 2
Placebo 2023 Treatment Timeline for Medical Study. Trial Name: NCT03968133 — Phase 2
~12 spots leftby Nov 2025